Platelet transfusions in adult thrombocytopenic ICU patients: Protocol for a sub-study of the PLOT-ICU cohort
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Platelet transfusions in adult thrombocytopenic ICU patients : Protocol for a sub-study of the PLOT-ICU cohort. / Anthon, Carl Thomas; Pène, Frédéric; Perner, Anders; Azoulay, Elie; Puxty, Kathryn; Van De Louw, Andry; Chawla, Sanjay; Castro, Pedro; Povoa, Pedro; Coelho, Luis; Metaxa, Victoria; Kochanek, Matthias; Liebregts, Tobias; Kander, Thomas; Sivula, Mirka; Møller, Morten Hylander; Russell, Lene.
I: Acta Anaesthesiologica Scandinavica, Bind 68, Nr. 3, 2024, s. 434-440.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Platelet transfusions in adult thrombocytopenic ICU patients
T2 - Protocol for a sub-study of the PLOT-ICU cohort
AU - Anthon, Carl Thomas
AU - Pène, Frédéric
AU - Perner, Anders
AU - Azoulay, Elie
AU - Puxty, Kathryn
AU - Van De Louw, Andry
AU - Chawla, Sanjay
AU - Castro, Pedro
AU - Povoa, Pedro
AU - Coelho, Luis
AU - Metaxa, Victoria
AU - Kochanek, Matthias
AU - Liebregts, Tobias
AU - Kander, Thomas
AU - Sivula, Mirka
AU - Møller, Morten Hylander
AU - Russell, Lene
N1 - Publisher Copyright: © 2023 Acta Anaesthesiologica Scandinavica Foundation.
PY - 2024
Y1 - 2024
N2 - Introduction: Platelet transfusions are frequently used in intensive care unit (ICU) patients, but contemporary epidemiological data are sparse. We aim to present contemporary international data on the use of platelet transfusions in adult ICU patients with thrombocytopenia. Methods: This is a protocol and statistical analysis plan for a post hoc sub-study of 504 thrombocytopenic patients from the ‘Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU)’. The primary outcome will be the number of patients receiving platelet transfusion in the ICU reported according to the type of product received (apheresis-derived versus pooled whole-blood-derived transfusions). Secondary platelet transfusion outcomes will include platelet transfusion volumes; timing of platelet transfusion; approach to platelet transfusion dosing (fixed dosing versus weight-based dosing) and platelet count increments for prophylactic transfusions. Secondary clinical outcomes will include the number of patients receiving red blood cell- and plasma transfusions during ICU stay; the number of patients who bled in the ICU, the number of patients who had a new thrombosis in the ICU, and the number of patients who died. The duration of follow-up was 90 days. Baseline characteristics and secondary clinical outcomes will be stratified according to platelet transfusion status in the ICU and severity of thrombocytopenia. Data will be presented descriptively. Conclusions: The outlined study will provide detailed epidemiological data on the use of platelet transfusions in adult ICU patients with thrombocytopenia using data from the large international PLOT-ICU cohort study. The findings will inform the design of future randomised trials evaluating platelet transfusions in ICU patients.
AB - Introduction: Platelet transfusions are frequently used in intensive care unit (ICU) patients, but contemporary epidemiological data are sparse. We aim to present contemporary international data on the use of platelet transfusions in adult ICU patients with thrombocytopenia. Methods: This is a protocol and statistical analysis plan for a post hoc sub-study of 504 thrombocytopenic patients from the ‘Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU)’. The primary outcome will be the number of patients receiving platelet transfusion in the ICU reported according to the type of product received (apheresis-derived versus pooled whole-blood-derived transfusions). Secondary platelet transfusion outcomes will include platelet transfusion volumes; timing of platelet transfusion; approach to platelet transfusion dosing (fixed dosing versus weight-based dosing) and platelet count increments for prophylactic transfusions. Secondary clinical outcomes will include the number of patients receiving red blood cell- and plasma transfusions during ICU stay; the number of patients who bled in the ICU, the number of patients who had a new thrombosis in the ICU, and the number of patients who died. The duration of follow-up was 90 days. Baseline characteristics and secondary clinical outcomes will be stratified according to platelet transfusion status in the ICU and severity of thrombocytopenia. Data will be presented descriptively. Conclusions: The outlined study will provide detailed epidemiological data on the use of platelet transfusions in adult ICU patients with thrombocytopenia using data from the large international PLOT-ICU cohort study. The findings will inform the design of future randomised trials evaluating platelet transfusions in ICU patients.
KW - critical care
KW - intensive care unit
KW - platelet transfusions
KW - thrombocytopenia
U2 - 10.1111/aas.14365
DO - 10.1111/aas.14365
M3 - Journal article
C2 - 38115558
AN - SCOPUS:85180233480
VL - 68
SP - 434
EP - 440
JO - Acta Anaesthesiologica Scandinavica
JF - Acta Anaesthesiologica Scandinavica
SN - 0001-5172
IS - 3
ER -
ID: 384656841